✓ Medically reviewed by  ·  Last reviewed: May 2026

Morgan Ellis

Pharmacy Researcher · 8 years experience

Pharmacy researcher with 8 years reviewing clinical drug information, generic formulation equivalence, and international pharmaceutical standards. Focuses on patient-facing accuracy in medication education.

Kisspeptin-10 Peptide: HPG-Axis Upstream Activator Research Guide

Kisspeptin-10 is the 10-amino-acid C-terminal fragment of the kisspeptin family of peptides — the upstream gatekeeper of the entire reproductive endocrine cascade. The molecule sits at the very top of the HPG axis, gating GnRH neuron activity, and through it controlling LH / FSH release and downstream gonadal steroidogenesis. For reproductive-endocrinology research, kisspeptin-10 is the canonical upstream-activator compound.

What is kisspeptin-10

Kisspeptin-10 (CAS 374675-21-5) is the active C-terminal fragment of native kisspeptin (encoded by the KISS1 gene). The full peptide family includes kisspeptin-54, -14, -13, and -10, all of which retain receptor-binding activity in the C-terminal 10 residues — making kisspeptin-10 the minimum active research-grade fragment. The molecule binds the KISS1R receptor (also called GPR54) on hypothalamic GnRH neurons.

Mechanism: the HPG-axis gatekeeper

The hypothalamic-pituitary-gonadal (HPG) axis controls all reproductive endocrinology. The axis has three sequential layers:

1. Hypothalamus — GnRH neurons release gonadotropin-releasing hormone in pulses
2. Pituitary — LH (luteinising hormone) and FSH (follicle-stimulating hormone) secretion in response to GnRH pulses
3. Gonads — testosterone (testes) or estrogen / progesterone (ovaries) production in response to LH / FSH

The discovery of kisspeptin in the early 2000s revealed a fourth layer upstream: kisspeptin neurons in the hypothalamus gate GnRH neuron activity. Without kisspeptin signalling, GnRH pulses don’t initiate (the phenotype of KISS1R-knockout mice is hypogonadotropic hypogonadism with absent puberty). Kisspeptin pulses drive GnRH pulses; GnRH pulses drive LH / FSH; LH / FSH drive gonadal steroidogenesis. The entire reproductive-endocrine cascade rests on kisspeptin signalling.

For research applications, this means kisspeptin-10 administration produces a sharp, controllable upstream stimulus to the HPG axis — the equivalent of “turning the system on” at its highest point of physiological control.

Research applications

Most-published research scenarios: infertility-investigation protocols (using kisspeptin-10 as a diagnostic challenge to characterise HPG-axis function); hypothalamic-amenorrhoea research (the phenotype most directly linked to disrupted kisspeptin signalling); polycystic ovary syndrome / PCOS research (where excessive kisspeptin tone is a candidate mechanism); IVF-protocol optimisation (kisspeptin-10 has been explored as a final-oocyte-maturation trigger alternative to hCG); male hypogonadotropic hypogonadism research; and fundamental reproductive-endocrinology research on the kisspeptin / GnRH / LH-FSH cascade.

Research dosing

Short half-life (~3-4 minutes) means kisspeptin-10 is administered as bolus SC injection or short IV infusion rather than sustained subcutaneous dosing. Published research protocols use single-bolus doses ranging from 0.1 to 32 nmol/kg with the LH response measured over 60-120 minutes post-administration. Continuous infusion protocols at lower doses are also published. The molecule’s brief plasma residence is a feature for diagnostic / challenge-test protocols where a sharp pulse and rapid clearance is the design.

Side-effect profile

Generally favourable in published research. The main consideration is that kisspeptin-10 produces measurable LH / FSH / testosterone or estrogen elevation in research subjects — which is the intended effect but should be accounted for in research-protocol design (transient supraphysiological steroid elevation depending on dose). No documented dependence liability, no significant cardiovascular signal, no sedation. The molecule is short-lived enough that washout is rapid.

Comparator and stacking

For HPG-axis research, kisspeptin-10 sits upstream of GnRH (which doesn’t have a current MedsBase catalogue presence) and ultimately of HCG (gonadotropin replacement). The mechanistic positioning: kisspeptin acts at the hypothalamic level; HCG acts at the gonadal level mimicking LH. The two approach reproductive endocrinology from opposite ends of the cascade. For full reproductive-cluster context see the HCG dose protocol guide and the HCG buying guide.

Storage and reconstitution

Lyophilized vials at -20 °C long-term, 2-8 °C working stock. Reconstitute with bacteriostatic water. Reconstituted solution at 2-8 °C with use within ~30 days; protect from light; never freeze-thaw.

FAQ

What does “upstream of GnRH” actually mean for research?

It means kisspeptin sits at a higher control point in the reproductive endocrine cascade. To study the entire HPG axis, you need either kisspeptin (gates GnRH), GnRH directly (gates LH/FSH), LH/FSH agonists (gate gonadal steroidogenesis), or the steroids themselves. Kisspeptin’s position lets you study the integrity of the entire cascade from the top down.

Is kisspeptin-10 the same as full-length kisspeptin?

Kisspeptin-10 is the minimum active C-terminal fragment. Native kisspeptin-54 has additional N-terminal residues that affect plasma half-life and pharmacokinetics but not receptor-binding activity. For most research-protocol applications, kisspeptin-10 is the standard form because the shorter sequence is easier to synthesise and the receptor pharmacology is identical.

Why is the half-life so short?

Native kisspeptin operates as a pulse signal — the physiological design includes rapid clearance to allow distinct pulses. The short half-life of kisspeptin-10 (~3-4 minutes) mirrors this physiological design. For research, the brief plasma residence is appropriate for bolus-challenge protocols and unsuitable for sustained-elevation protocols.

Can kisspeptin-10 be used for IVF research?

Yes — this is one of the most-published research applications. Kisspeptin-10 has been explored as a final-oocyte-maturation trigger alternative to hCG, with the rationale that the more-physiological signalling pattern may reduce ovarian hyperstimulation syndrome risk. Published Phase 2 IVF data is favourable.

What’s the typical research dose?

Single SC or short IV bolus, 0.1 to 32 nmol/kg depending on protocol design. The LH response is measured over 60-120 minutes post-administration as the primary endpoint.

Storage protocol?

Lyophilized at -20 °C long-term, 2-8 °C working; reconstituted at 2-8 °C use within 30 days; protect from light; never freeze-thaw.

Bottom line

Kisspeptin-10 is the upstream gatekeeper of the entire reproductive endocrine cascade and the canonical research-grade compound for HPG-axis investigation. The molecule’s position at the top of the kisspeptin / GnRH / LH-FSH / gonadal-steroid cascade lets researchers probe the integrity of the system from its highest point of physiological control. For fertility research, infertility investigation, IVF-protocol optimisation, hypothalamic-amenorrhoea research, and fundamental reproductive endocrinology, kisspeptin-10 is the appropriate upstream-activator molecule.

Written by

Sophie Chen

Pharmaceutical Content Researcher · 8 years experience

Sophie Chen is a pharmaceutical content researcher with 8 years covering generic medication access and clinical pharmacology. She specialises in international regulatory frameworks, bioequivalence standards, and patient-facing education on therapeutic drug classes. She is not a clinician.